Evidence map›Paper›PMID 39461878›Full record

ArticleJournal for immunotherapy of cancer2024

TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance.

Tony R Reid, Bryan Oronsky, Jeannie Williams, Scott Caroen, Anthony Conley

Registry-linked trialAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04673942 (An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04673942 phase2active not recruitingnot on this map

An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors

TypeinterventionalSponsorEpicentRx, Inc.Ran2021 to 2027Enrolled140ConditionsSolid Tumor, Adult, Cancer, Neoplasms, SarcomaArmsAdAPT-001, Checkpoint Inhibitor, Immune
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Targeting innate immunity to overcome immune evasion in HPV-associated cancers.Frontiers in cellular and infection microbiology · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tony R ReidEpicentRx Inc, La Jolla, California, USA.
Bryan OronskyEpicentRx Inc, La Jolla, California, USA boronsky@epicentrx.com.ORCID 0000-0002-3940-6329
Jeannie WilliamsEpicentRx Inc, La Jolla, California, USA.
Scott CaroenEpicentRx Inc, La Jolla, California, USA.
Anthony ConleySarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME before taking part. AdAPT-001 is an oncolytic adenovirus that expresses a transforming growth factor beta (TGF-β) trap to neutralize active TGF-β. This editorial proposes that the TGF-β trap of AdAPT-001 reverses the immunosuppressive environment of tumor cells, and thus makes these tumors susceptible to CIs like the anti-PD-1 agent, nivolumab, and potentially other therapies as well.

Indexed as

Immune Checkpoint InhibitorsNeoplasmsTransforming Growth Factor betaClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDrug Resistance, NeoplasmHumansImmune Checkpoint InhibitorsTransforming Growth Factor betaImmune Checkpoint InhibitorImmunosuppressionOncolytic virusTumor microenvironment - TME

Identifiers

PMID39461878
PMCPMC11529498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.